• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    Cleveland BioLabs, Inc. (CBLI)

    -NasdaqCM
    3.41 Down 0.16(4.48%) Feb 5, 4:00PM EST
    ProfileGet Profile for:
    Cleveland BioLabs, Inc.
    73 High Street
    Buffalo, NY 14203
    United States - Map
    Phone: 716-849-6810
    Fax: 716-849-6820
    Website: http://www.cbiolabs.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:13

    Business Summary 

    Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a nanoparticle-formulated recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, flagellin. It has license agreements and collaborations with the Cleveland Clinic Foundation and Roswell Park Cancer Institute. Cleveland BioLabs, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cleveland BioLabs, Inc.

    Key Executives 
     PayExercised
    Dr. Yakov N. Kogan Ph.D., MBA, 43
    Co-Founder, Chief Exec. Officer and Director
    312.00K0.00
    Dr. Andrei V. Gudkov Ph.D., D.Sci., 60
    Co-Founder, Chief Scientific Officer and Director
    119.00K0.00
    Mr. C. Neil Lyons CPA, 59
    Chief Financial Officer and Exec. VP
    293.00K0.00
    Dr. Langdon Miller M.D.,
    Pres and Chief Medical Officer
    N/AN/A
    Ms. Rachel Levine ,
    VP of Investor Relations
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders